Alzheimer's disease
VYGRVoyager TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1a data readout for VY7523 (formerly VT- TAU01) [anti-tau antibody] in Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
Q4 '24- Ph1a SAD data demonstrated acceptable safety, tolerability, & immunogenicity profile. Initiated MAD study with Initial PET imaging data in H2 2026. 11/10/25:- Dosing ongoing in third and final MAD cohort; initial tau PET imaging data expected in H2 2026. 03/09/26:- MAD Ph1 AD trial completed enrollment; tau PET imaging data remain expected in H2 2026. 05/07/26:- Reiterated expectation for tau PET imaging efficacy data from ongoing MAD AD trial in H2 2026. 08/06/26:- MAD trial tau PET imaging data now expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.